Screener

Eligibility screening

LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis

Sponsored by Eli Lilly and CompanyStudy detailsClinicalTrials.gov

41 US sites in AZ, CA, CO, FL +15

Before we begin

Who are you filling this out for?

Your answer affects how the questions are phrased.